Michael Shalmi

Michael Shalmi is currently Chief Executive Officer at Momentum Energy Hanstholm K, Momentum Energy Jutlandia P, Shalmi Invest ApS, Shalmi Holding ApS, Shalmi Consulting APS, Momentum Energy Selandia K, and Momentum Energy Jutlandia Development.
K.
Dr. Shalmi is Chairman at Active Biotech AB, Momentum Energy Group A, Curexsys GmbH, Curexsys AG, and Momentum Energy Holdings ApS.
Dr. Shalmi is Director at Sonion Holdco.
A and Momentum Energy Karrebæk Holding K.
Dr. Shalmi is Member-Supervisory Board at ERT Holdco A, Xellia Holdco A, and Novo Invest 1 A. Former roles include Director at Aerocrine AB, SYNLAB International GmbH, SYNLAB Ltd., and Env Holdcoco AS.
Dr. Shalmi was Independent Director at Orexo AB from 2010 to 2018, Managing Director at Novo Principal Investments from 2016 to 2019, Director at SYNLAB Ltd. from 2017 to 2019, Director at Env Holdcoco AS from 2018 to 2019, Vice President-Clinical Operations Management at Novo Nordisk A, Member-Supervisory Board at Evotec SE, Senior Partner at Novo Holdings A from 2009 to 2016, and Member-Supervisory Board at ERT, Inc. Education includes a doctorate from the University of Copenhagen and an MBA from Scandinavian International Management Institute.